SELB Selecta Biosciences, Inc.

13.10
+0  (3%)
Previous Close 12.73
Open 12.72
Price To book 0.00
Market Cap N/A
Shares 0
Volume 11,601
Short Ratio 0.00
Av. Daily Volume 46,437

SEC filingsSee all SEC filings

  1. REVOKED - Commission order revoking Exchange Act registration (Section 12(j)) 13982552
  2. 8-K - Current report 04628351
  3. 8-K - Current report 031068414
  4. 8-K - Current report 03969278
  5. 8-K - Current report 03945094

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dosing commenced late October 2016. Initial data due by the end of June 2017, with trial to be completed in 2017.
SEL-212
Tophaceous gout

Latest News

  1. ETFs with exposure to Selecta Biosciences, Inc. : April 26, 2017
  2. Selecta Biosciences to Present at Two Upcoming Investor Conferences in May
  3. Selecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 30, 2017
  4. Edited Transcript of SELB earnings conference call or presentation 27-Mar-17 9:00pm GMT
  5. Selecta Biosciences to Present at the Needham Healthcare Conference on April 4, 2017
  6. Selecta Biosciences Announces Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update
  7. Selecta Biosciences to Report Fourth Quarter and Year End 2016 Financial Results on Monday, March 27, 2017
  8. Lonza and Selecta Biosciences Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy for Treatment of Methylmalonic Acidemia
  9. Selecta Biosciences Announces Preclinical Data Showing SVP-Rapamycin’s Potential Benefit in Treatment of Pompe Disease
  10. Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Peanut Allergy Therapeutic Vaccine and Celiac Disease Treatment
  11. Selecta Biosciences to Participate in Two Investor Conferences in February
  12. Selecta Biosciences (SELB) Enters Oversold Territory
  13. Selecta Biosciences (SELB): Strong Industry, Solid Earnings Estimate Revisions
  14. Selecta Biosciences, Inc. – Value Analysis (NASDAQ:SELB) : December 21, 2016
  15. Selecta Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : SELB-US : December 20, 2016
  16. A new name and new fund will ensure Cambridge's Flagship 'feels like a startup'
  17. Increased Earnings Estimates Seen for Selecta Biosciences (SELB): Can It Move Higher?
  18. Is Ignyta Inc (RXDX) A Good Stock To Buy?